心脏骤停后联合使用VA-ECMO与主动脉内球囊反搏
该研究为大规模多中心30天队列研究,纳入2010–2017年东京CCU网络登记中ROSC后接受VA-ECMO治疗的935例患者,按是否联合IABP分为ECMO+IABP组(n=762)与单用ECMO组(n=173)。粗分析显示联合组30天良好神经功能预后显著优于单用组(35% vs 25%,log-rank P<0.001);ACS亚组中联合组同样显著更优(34% vs 18%,P<0.001),非ACS亚组无显著差异(38% vs 32%,P=0.11)。倾向性评分匹配后结果相似。提示ROSC后VA-ECMO联合IABP可能与更好神经预后相关,尤其合并ACS者。
要点
- ROSC后接受VA-ECMO的患者,联合IABP组30天良好神经功能预后为35%,单用ECMO组为25%(log-rank P<0.001)。
- ACS病因亚组中,联合IABP组良好神经预后为34%,单用ECMO组为18%(log-rank P<0.001)。
- 非ACS病因亚组中,联合IABP组与单用ECMO组良好神经预后无显著差异(38% vs 32%,log-rank P=0.11)。
- 倾向性评分匹配调整背景后,上述结果相似。
- 该研究为观察性队列,联合IABP与更好预后为相关性,不能据此确立常规联合推荐。
适用人群与场景
- 2010–2017年东京CCU网络登记中,送达急诊室后ROSC并接受VA-ECMO治疗的成人患者(共935例)。
- 亚组分析按心脏骤停病因分为ACS与非ACS。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及IABP的置入时机、参数设置或VA-ECMO的管理方案。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:大规模、多中心、30天队列研究;数据来源为东京心血管重症监护网络登记(2010–2017年)。
- 样本量:80,716例送达急诊室患者中,935例ROSC后接受VA-ECMO治疗;ECMO+IABP组n=762,单用ECMO组n=173。
- 主要终点:30天良好神经功能预后。粗分析:联合组35% vs 单用组25%(log-rank P<0.001)。
- ACS亚组:联合组34% vs 单用组18%(log-rank P<0.001);非ACS亚组:38% vs 32%(log-rank P=0.11)。
- 采用倾向性评分匹配进行背景调整后,结果相似。
证据类型、等级与局限
- 证据类型:多中心观察性队列研究(非随机对照试验)。
对床旁实践的改变
- 对于ROSC后因心脏骤停接受VA-ECMO的患者,尤其是ACS病因者,联合IABP可能与更好的30天神经功能预后相关,可考虑作为个体化辅助措施。
- 非ACS病因患者中联合IABP未显示显著获益(38% vs 32%,P=0.11),不应仅凭此研究常规联合。
- 该研究为观察性队列,不能改变「IABP常规联合VA-ECMO」的推荐级别;临床决策仍需结合患者具体情况与团队经验。
指南或共识出处
- 原文未提及指南或共识名称;研究数据来自东京心血管重症监护网络登记(Tokyo Cardiovascular Care Unit Network Registry)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We investigated whether intra-aortic balloon pump (IABP) combined with venoarterial extracorporeal membrane oxygenation (VA-ECMO) was associated with favourable neurological outcomes for patients after the return of spontaneous circulation (ROSC). Moreover, we evaluated the aetiology of cardiac arrest on the effectiveness of this therapy in a sub-study.
BACKGROUND: There is insufficient research on the optimal combination of machines for patients after ROSC is not established.
METHODS: This is a large-scale, multicentre, 30-day cohort study. Among 80,716 patients who delivered to the emergency room, 935 patients treated with VA-ECMO after ROSC were included using the data from the Tokyo Cardiovascular Care Unit Network Registry between 2010 and 2017. The study patients were stratified according to the use of IABP [the ECMO + IABP group (n = 762) vs. the ECMO-alone group (n = 173)]. We also evaluated the cause of cardiac arrest [acute coronary syndrome (ACS) and non-ACS] in the sub-study. To adjust the patients' backgrounds, we used the propensity score matching for additional analyses. The endpoint was 30-day favourable neurological outcome.
RESULTS: The ECMO + IABP group showed significantly better neurological outcomes than the ECMO-alone group (crude; 35% vs. 25%; log-lank P < 0.001). In the ACS subgroup, the ECMO + IABP group showed significantly better neurological outcome (crude; 34% vs. 18%; log-lank P < 0.001), but not in the non-ACS subgroup (crude; 38% vs. 32%; log-lank P = 0.11). These results are similar after adjustments to their backgrounds using propensity matching.
CONCLUSIONS: Compared to VA-ECMO alone, the combined use of VA-ECMO and IABP is associated with better neurological outcomes after ROSC, especially in complicated ACS.
参考来源
- Kuroki N, Nagao K, Otsuka T, et al. Combined use of venoarterial extracorporeal membrane oxygenation and intra-aortic balloon pump after cardiac arrest. Resuscitation. 2021. PMID: 34314778. doi:10.1016/j.resuscitation.2021.07.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。